Search+Business News›Markets›Stocks›News›Picking the right pharma stock is getting harder; so pick a portfolio: 20 stocks with -23% to +22% downside to upside potentialInvestment IdeasSynopsisFor Indian pharma, the regulatory risk is still real. A US FDA inspection can still cause trouble. A plant making an important product or generating a chunk of US revenue can face adverse observations, delayed approvals, or restrictions. Even if the long-term business is intact, the stock can remain under pressure for months. Stock Reports Plus, powered by Refinitiv, is a comprehensive report that evaluates five key components of 4,000+ listed stocks – earnings, fundamentals, relative valuation, risk, and price momentum – to generate standardised scores. The simple average of the above-mentioned five component ratings is normally distributed to reach an average score.As the market makes a recovery, be clear about why and where you are investing money. Are you making a tactical investment? Money being put in for, say, the next three to nine months. Or is the money being put in for more than three years? This distinction is important because it will not only decide which stocks to buy, and the way they are bought, even if the sector is the same.There are only a handful of sectors where India has built an ETMarkets.com 26 mins readAug 09, 2026, 11:36:00 PM ISTGift this Story to your friendsFONT SIZEAbcSmallAbcMediumAbcLargeSAVEPRINTCOMMENTContinue reading with one of these options:Limited AccessFreeLogin to get access to some exclusive stories & personalised newslettersLogin NowUnlimited AccessStarting @ Rs120/monthGet access to exclusive stories, expert opinions & in-depth stock reportsSubscribe NowETUh-oh! This is an exclusive story available for selected readers only.Worry not. You’re just a step away.What’s Included withETPrime Membership
Picking the right pharma stock is getting harder; so pick a portfolio: 20 stocks with -23% to +22% downside to upside potential
For Indian pharma, the regulatory risk is still real. A US FDA inspection can still cause trouble. A plant making an important product or generating a chunk of US revenue can face adverse observations, delayed approvals, or restrictions. Even if the long-term business is intact, the stock can remain under pressure for months. Stock Reports Plus, powered by Refinitiv, is a comprehensive report that evaluates five key components of 4,000+ listed stocks – earnings, fundamentals, relative valuation, risk, and price momentum – to generate standardised scores. The simple average of the above-mentioned five component ratings is normally distributed to reach an average score.
FDA regulatory headwinds pressure Indian pharma; 20-stock portfolio strategy suggested with -23% to +22% return range vs. single-stock bets. Regulatory risk in mature sectors teaches tech investors: diversification hedges governance concentration where idiosyncratic risk trumps fundamental thesis.
